The informative value of preoperative prostate-specific antigen in determination of the likelihood of recurrent prostate cancer after radical prostatectomy
https://doi.org/10.17650/1726-9776-2006-2-3-34-36
Abstract
Materials and Methods. The results of examination and treatment of 163 males who had undergone radical retropubic prostatectomy (RRP) with bilateral pelvic lymphadenectomy for clinically locally advanced prostate cancer (PC) (T1aN0M0-to-cT2bN0M0) were studied. The patients’ mean age was 63.5 years and ranged from 41 to 74 years. After RRP, the duration of a follow-up averaged 46.6±2.7 months and ranged from 24 to 81 months. Digital rectal study, determination of serum prostate-specific antigen (PSA) and its density, transrectal multifocal prostate biopsy under ultrasound guidance, and, if required (PSA more than 20 ng/ml or a total of above 7 Glisson scores), computed tomography and scintigraphy of skeletal bones were performed in all the patients. The postoperative examination involved postmortem examination and measurement of serum PSA levels over time.
Results. The study has revealed that there is an clear tendency for an increase in the frequency of other poor signs with elevated preoperative PSA levels.
Conclusion. The findings have indicated that there is a direct and statistically significant correlation between the preoperative values of total PSA, its density, and the possible outcomes of RRP.
About the Authors
Ye. I. Veliyev
Russian Medical Academy of Postgraduate Education
Russian Federation
Moscow
Russian Federation
Moscow
S. B. Petrov
S.M. Kirov Military Medical Academy
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
M. I. Katibov
Russian Medical Academy of Postgraduate Education
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Brawer M.K., Benson M.C., Bostwick D.G. et al. Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999; 17:206–21.
2. Chang S.S., Gaudin P.B., Reuter V.E., Heston W.D.W. Prostate-specific membrane antigen: present and future applications. Urology 2000; 55: 622–9.
3. Jensen O.M., Esteve J., Moller H., Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167–256.
4. Black R.J., Bray F., Ferlay J., Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33:1075–107.
5. Данилова Т.В. Заболеваемость и смертность от злокачественных новообразований предстательной железы в России. Тезисы докл. IX Всероссийской конференции онкологов «Гормонозависимые опухоли»: СПб., 2002. с. 35–6.
6. Eastham J.A., Scardino P.T. Radical prostatectomy. In: Campbell’s Urology. Eds. P.S. Walsh et al. Philadelphia; 1999. p. 2547–64.
7. Gibbons R.P., Cole B.C., Richardson G. Adjuvant radiotherapy following radical prostate-ctomy: Results and complications. J Urol 1986;135: 65–8.
8. Myers R.P., Larson-Keller J.J., Bergstralh E.J. et al. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: Results of long term follow-up. Urology 1992; 174: 910–5.
9. Kent E.C., Hussain M.H.A. The rationale for adjuvant chemotherapy for high-risk prostate cancer. Curr Opin Urol 2003;13:123–31.
Review
For citations:
Veliyev Ye.I., Petrov S.B., Katibov M.I. The informative value of preoperative prostate-specific antigen in determination of the likelihood of recurrent prostate cancer after radical prostatectomy. Cancer Urology. 2006;2(3):34-36. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-3-34-36
Views:
293
Email this article 